Surrozen, Inc. (NASDAQ:SRZN) Receives Average Rating of “Moderate Buy” from Analysts

Posted by Stanley Muller on May 16th, 2026

Surrozen, Inc. (NASDAQ:SRZN – Get Free Report) has received a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $42.00.

A number of equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and issued a $44.00 target price (up from $36.00) on shares of Surrozen in a research note on Thursday, May 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a research note on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating and issued a $40.00 price objective on shares of Surrozen in a research note on Tuesday, March 24th. TD Cowen initiated coverage on Surrozen in a research note on Tuesday, April 21st. They issued a “buy” rating for the company. Finally, Wall Street Zen upgraded Surrozen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th.

Get Our Latest Stock Report on Surrozen

Surrozen Price Performance

Shares of Surrozen stock opened at $28.15 on Friday. The firm has a market capitalization of $326.82 million, a price-to-earnings ratio of -0.75 and a beta of 0.59. Surrozen has a one year low of $5.90 and a one year high of $35.00. The business has a 50-day simple moving average of $28.75 and a 200 day simple moving average of $22.98.

Surrozen (NASDAQ:SRZN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($11.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The company had revenue of $5.00 million for the quarter, compared to analyst estimates of $4.00 million. Surrozen had a negative net margin of 4,810.50% and a negative return on equity of 4,055.04%. On average, sell-side analysts expect that Surrozen will post -7.2 EPS for the current year.

Insiders Place Their Bets

In related news, COO Charles O. Williams sold 2,036 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $67,859.88. Following the transaction, the chief operating officer owned 16,571 shares in the company, valued at approximately $552,311.43. This represents a 10.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Craig C. Parker sold 4,524 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $150,784.92. Following the completion of the transaction, the chief executive officer owned 16,553 shares in the company, valued at approximately $551,711.49. The trade was a 21.46% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have bought 170,878 shares of company stock worth $4,232,976 and have sold 8,144 shares worth $271,440. 31.74% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Surrozen

Several institutional investors have recently bought and sold shares of SRZN. Geode Capital Management LLC lifted its stake in Surrozen by 22.6% in the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after purchasing an additional 5,702 shares during the last quarter. Armistice Capital LLC bought a new stake in Surrozen during the 2nd quarter valued at $536,000. Vanguard Group Inc. raised its holdings in Surrozen by 21.7% during the 3rd quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock valued at $3,433,000 after acquiring an additional 47,468 shares during the period. Acuta Capital Partners LLC grew its position in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC purchased a new position in shares of Surrozen in the third quarter valued at $889,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

(Get Free Report)

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.